Article(id=1330225533830410392, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225440532312310, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.05.022, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1626451200000, receivedDateStr=2021-07-17, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080081660, onlineDateStr=2026-11-19, pubDate=1652112000000, pubDateStr=2022-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080081660, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080081660, creator=13701087609, updateTime=1795080081660, updator=13701087609, issue=Issue{id=1330225440532312310, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='5', pageStart='489', pageEnd='637', issueExtLink='null', onlineDate='null', pubDate='1652112000000', pubDateStr='2022-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080059416, creator='13701087609', updateTime=1795084724062, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245006004171450, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225440532312310, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245006004171451, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225440532312310, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=620, endPage=627, ext={EN=ArticleExt(id=1330225534002376857, articleId=1330225533830410392, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in drug use for dry eye disease, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Dry eye disease (DED), also known as keratoconjunctivitis sicca (KCS), is a disease caused by unstable lacrimal gland secretion, which leads to abnormal tear quality or quantity and eye surface damage, resulting in a variety of ocular symptoms, such as inflammation, pain, redness and itching. DED can also induce by environmental and genetic factors. Although there are many kinds of drugs for DED on the market, the product penetration rate is low, so there is still a great demand in clinic. This paper reviewed the current clinical drug use of DED and the research progress of global drugs for DED in research, in order to provide reference for clinical drug use.

, authors=Miao FANG1, 2, Degang WANG2, Peiqing LIU1, *, authorsList=Miao FANG, Degang WANG, Peiqing LIU, authorCompany=null, correspAuthors=Peiqing LIU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330225534228869274, articleId=1330225533830410392, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=干眼症的用药研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

干眼症(dry eye disease,DED)又称干燥性角膜结膜炎,是由于泪腺分泌不稳定导致泪液质或量异常及眼表损害,致使眼部出现如炎症、疼痛、发红及发痒等多种症状的一种疾病,环境及遗传等因素均可诱发DED。尽管目前已有多种针对DED的药物上市,但产品渗透率较低,因此临床仍有较大需求。该文就目前DED临床用药及全球DED在研药物的研究进展作一综述,以期为临床用药提供参考。

, authors=房淼1, 2, 王德刚2, 刘培庆1, *, authorsList=房淼, 王德刚, 刘培庆, authorCompany=null, correspAuthors=刘培庆, authorNote=

房淼,博士,研究方向:药理学。

, correspAuthorsNote=
刘培庆,主任药师,教授,研究方向:心血管药理学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=KY3SWmmD/kHmUqpPzd20/w==, magXml=ToEF0LFpvm2ef3BbzAAxpQ==, pdfUrl=null, pdf=iGVT8BANqoF8aJe4dCUCBg==, pdfFileSize=1643426, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=le5FH0m4XLmutlz+RpCHYQ==, mapNumber=null, fund=null)}, authors=[Author(id=1330225534576996516, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225534656688295, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534576996516, language=EN, stringName=Miao FANG, firstName=Miao, middleName=null, lastName=FANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China
2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225534736380072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534576996516, language=CN, stringName=房淼, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中山大学药学院,广东 广州 510275
2.珠海联邦制药股份有限公司,广东 珠海 528467, bio={"content":"

房淼,博士,研究方向:药理学。

"}, bioImg=null, bioContent=

房淼,博士,研究方向:药理学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225534409224349, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=1., ext=[AuthorCompanyExt(id=1330225534417612958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China), AuthorCompanyExt(id=1330225534426001567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中山大学药学院,广东 广州 510275)]), AuthorCompany(id=1330225534480527520, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=2., ext=[AuthorCompanyExt(id=1330225534488916129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China), AuthorCompanyExt(id=1330225534501499042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.珠海联邦制药股份有限公司,广东 珠海 528467)])]), Author(id=1330225534841237674, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225534933512364, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534841237674, language=EN, stringName=Degang WANG, firstName=Degang, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225534992232621, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534841237674, language=CN, stringName=王德刚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.珠海联邦制药股份有限公司,广东 珠海 528467, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225534480527520, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=2., ext=[AuthorCompanyExt(id=1330225534488916129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China), AuthorCompanyExt(id=1330225534501499042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.珠海联邦制药股份有限公司,广东 珠海 528467)])]), Author(id=1330225535067730095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225535139033265, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225535067730095, language=EN, stringName=Peiqing LIU, firstName=Peiqing, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225535206142130, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225535067730095, language=CN, stringName=刘培庆, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中山大学药学院,广东 广州 510275, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225534409224349, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=1., ext=[AuthorCompanyExt(id=1330225534417612958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China), AuthorCompanyExt(id=1330225534426001567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中山大学药学院,广东 广州 510275)])])], keywords=[Keyword(id=1330225535302611123, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, language=EN, orderNo=1, keyword=dry eye disease), Keyword(id=1330225535378108596, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, language=EN, orderNo=2, keyword=ocular surface lesion), Keyword(id=1330225535436828855, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, language=EN, orderNo=3, keyword=clinical medication), Keyword(id=1330225535503937720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, language=CN, orderNo=1, keyword=干眼症), Keyword(id=1330225535575240889, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, language=CN, orderNo=2, keyword=眼表损害), Keyword(id=1330225535633961146, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, language=CN, orderNo=3, keyword=临床用药)], refs=[Reference(id=1330225537487843518, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=中华医学会眼科学分会角膜病学组. 干眼临床诊疗专家共识(2013年)节选[J]. 中国社区医师, 2013, 29(21): 11-12., articleTitle=null, refAbstract=null), Reference(id=1330225537554952383, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=杨建军. 巩膜扣带术和干眼的相关性的临床研究[D]. 广西: 广西中医药大学, 2019., articleTitle=null, refAbstract=null), Reference(id=1330225537634644160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=余穑婕, 陈子林. 干眼的定义与分类的研究现状[J]. 中国临床新医学, 2019, 12(7): 801-804., articleTitle=null, refAbstract=null), Reference(id=1330225537693364418, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=McDonald M, Patel DA, Keith MS, et al. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review[J]. Ocul Surf, 2016, 14(2): 144-167., articleTitle=null, refAbstract=null), Reference(id=1330225537773056195, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index[J]. Arch Ophthalmol, 2000, 118(5): 615-621., articleTitle=null, refAbstract=null), Reference(id=1330225537835970756, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Grubbs JR Jr, Tolleson-Rinehart S, Huynh K, et al. A review of quality of life measures in dry eye questionnaires[J]. Cornea, 2014, 33(2): 215-218., articleTitle=null, refAbstract=null), Reference(id=1330225537919856837, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Anon. Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the international dry eye workshop (2007)[J]. Ocul Surf, 2007, 5(2): 108-152., articleTitle=null, refAbstract=null), Reference(id=1330225537978577094, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Bron AJ. Diagnosis of dry eye[J]. Surv Ophthalmol, 2001, 45(2): S221-S226., articleTitle=null, refAbstract=null), Reference(id=1330225538041491655, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=张辉, 李艳芳, 管玉颜. 干眼症的临床诊断[J]. 中国实验诊断学, 2009, 13(7): 940-941., articleTitle=null, refAbstract=null), Reference(id=1330225538116989128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Tomlinson A, Khanal S, Ramaesh K, et al. Tear film osmolarity: determination of a referent for dry eye diagnosis[J]. Invest Ophthalmol Vis Sci, 2006, 47(10): 4309-4315., articleTitle=null, refAbstract=null), Reference(id=1330225538205069513, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease[J]. Cornea, 2004, 23(8): 762-770., articleTitle=null, refAbstract=null), Reference(id=1330225538263789770, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Lemp MA. Management of dry eye disease[J]. Am J Manag Care, 2008, 14(3): S88-S101., articleTitle=null, refAbstract=null), Reference(id=1330225538326704331, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=李谋, 史瑾, 杨小琳, 等. 人工泪液在干眼症中的应用进展[J]. 中国现代医生, 2018, 56(34): 162-164., articleTitle=null, refAbstract=null), Reference(id=1330225538398007500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Choi HY, Lee YH, Lim CH, et al. Assessment of respiratory and systemic toxicity of benzalkonium chloride following a 14-day inhalation study in rats[J]. Part Fibre Toxicol, 2020, 17(1): 5., articleTitle=null, refAbstract=null), Reference(id=1330225538460922061, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Vitoux MA, Kessal K, Melik Parsadaniantz S, et al. Benzalkonium chloride-induced direct and indirect toxicity on corneal epithelial and trigeminal neuronal cells: proinflammatory and apoptotic responses in vitro[J]. Toxicol Lett, 2020, 319: 74-84., articleTitle=null, refAbstract=null), Reference(id=1330225538523836622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells[J]. Adv Ther, 2011, 28(6): 501-510., articleTitle=null, refAbstract=null), Reference(id=1330225538599334095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Kim YH, Jung JC, Jung SY, et al. Comparison of the efficacy of fluorometholone with and without benzalkonium chloride in ocular surface disease[J]. Cornea, 2016, 35(2): 234-242., articleTitle=null, refAbstract=null), Reference(id=1330225538662248656, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Epstein SP, Ahdoot M, Marcus E, et al. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells[J]. J Ocul Pharmacol Ther, 2009, 25(2): 113-119., articleTitle=null, refAbstract=null), Reference(id=1330225538720968913, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Ayaki M, Iwasawa A. Cell viability of four corneoconjunctival cell lines exposed to five preservatives and a surfactant used for infection control in eyedrops[J]. Biocontrol Sci, 2011, 16(3): 117-121., articleTitle=null, refAbstract=null), Reference(id=1330225538796466388, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Galletti JG, Gabelloni ML, Morande PE, et al. Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model[J]. Mucosal Immunol, 2013, 6(1): 24-34., articleTitle=null, refAbstract=null), Reference(id=1330225538863575253, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Lin Z, He H, Zhou T, et al. A mouse model of limbal stem cell deficiency induced by topical medication with the preservative benzalkonium chloride[J]. Invest Ophthalmol Vis Sci, 2013, 54(9): 6314-6325., articleTitle=null, refAbstract=null), Reference(id=1330225538926489814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas[J]. Invest Ophthalmol Vis Sci, 1980, 19(3): 308-313., articleTitle=null, refAbstract=null), Reference(id=1330225538993598679, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye[J]. Cochrane Database Syst Rev, 2017, 2(2): CD009327., articleTitle=null, refAbstract=null), Reference(id=1330225539060707544, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Bradley JC, Bradley RH, McCartney DL, et al. Serum growth factor analysis in dry eye syndrome[J]. Clin Exp Ophthalmol, 2008, 36(8): 717-720., articleTitle=null, refAbstract=null), Reference(id=1330225539123622105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease[J]. Br J Ophthalmol, 2004, 88(5): 647-652., articleTitle=null, refAbstract=null), Reference(id=1330225539203313882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Moon J, Ko JH, Yoon CH, et al. Effects of 20% human serum on corneal epithelial toxicity induced by benzalkonium chloride: in vitro and clinical studies[J]. Cornea, 2018, 37(5): 617-623., articleTitle=null, refAbstract=null), Reference(id=1330225539274617051, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=李海燕, 庞国祥. 眼表黏蛋白的研究进展[J]. 国际眼科纵览, 2004, 28(3): 150-154., articleTitle=null, refAbstract=null), Reference(id=1330225539345920220, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Stephens DN, McNamara NA. Altered mucin and glycoprotein expression in dry eye disease[J]. Optom Vis Sci, 2015, 92(9): 931-938., articleTitle=null, refAbstract=null), Reference(id=1330225539413029085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Watanabe H. Medical treatment for dry eye in Japan[J]. Invest Ophthalmol Vis Sci, 2018, 59(14): DES116-DES120., articleTitle=null, refAbstract=null), Reference(id=1330225539509498078, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Kawashima M, Yamada M, Suwaki K, et al. A clinic-based survey of clinical characteristics and practice pattern of dry eye in Japan[J]. Adv Ther, 2017, 34(3): 732-743., articleTitle=null, refAbstract=null), Reference(id=1330225539610161375, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Cowlen MS, Zhang VZ, Warnock L, et al. Localization of ocular P2Y2 receptor gene expression by in situ hybridization[J]. Exp Eye Res, 2003, 77(1): 77-84., articleTitle=null, refAbstract=null), Reference(id=1330225539681464546, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Li Y, Kuang K, Yerxa B, et al. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl- and fluid secretion[J]. Am J Physiol Cell Physiol, 2001, 281(2): C595-C602., articleTitle=null, refAbstract=null), Reference(id=1330225539790516451, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Amano S, Inoue K. Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction[J]. Clin Ophthalmol, 2017, 11: 1677-1682., articleTitle=null, refAbstract=null), Reference(id=1330225539870208228, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Shigeyasu C, Hirano S, Akune Y, et al. Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects[J]. Curr Eye Res, 2015, 40(9): 878-883., articleTitle=null, refAbstract=null), Reference(id=1330225539954094309, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Hwang HS, Sung YM, Lee WS, et al. Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops[J]. Cornea, 2014, 33(9): 935-941., articleTitle=null, refAbstract=null), Reference(id=1330225540033786086, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Gong L, Sun X, Ma Z, et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore[J]. Br J Ophthalmol, 2015, 99(7): 903-908., articleTitle=null, refAbstract=null), Reference(id=1330225540134449383, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test[J]. Dig Dis Sci, 2009, 54(7): 1500-1507., articleTitle=null, refAbstract=null), Reference(id=1330225540209946856, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Kato K, Miyake K, Kondo N, et al. Conjunctival goblet cell density following cataract surgery with diclofenac versus diclofenac and rebamipide: a randomized trial[J]. Am J Ophthalmol, 2017, 181: 26-36., articleTitle=null, refAbstract=null), Reference(id=1330225541816365290, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Kashima T, Itakura H, Akiyama H, et al. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal[J]. Clin Ophthalmol, 2014, 8: 1003-1010., articleTitle=null, refAbstract=null), Reference(id=1330225541887668459, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Mantelli F, Argueso P. Functions of ocular surface mucins in health and disease[J]. Curr Opin Allergy Clin Immunol, 2008, 8(5): 477-483., articleTitle=null, refAbstract=null), Reference(id=1330225541950583020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Arimoto A, Kitagawa K, Mita N, et al. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjogren syndrome patients with or without punctal occlusions[J]. Cornea, 2014, 33(8): 806-811., articleTitle=null, refAbstract=null), Reference(id=1330225542021886189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients[J]. Cornea, 2009, 28(9): 1023-1027., articleTitle=null, refAbstract=null), Reference(id=1330225542097383662, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Baudouin C. A new approach for better comprehension of diseases of the ocular surface[J]. J Fr Ophtalmol, 2007, 30(3): 239-246., articleTitle=null, refAbstract=null), Reference(id=1330225542156103919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Anon. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007)[J]. Ocul Surf, 2007, 5(2): 75-92., articleTitle=null, refAbstract=null), Reference(id=1330225542214824176, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Suzuki M, Massingale ML, Ye F, et al. Tear osmolarity as a biomarker for dry eye disease severity[J]. Invest Ophthalmol Vis Sci, 2010, 51(9): 4557-4561., articleTitle=null, refAbstract=null), Reference(id=1330225542281933041, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Tashbayev B, Utheim TP, Utheim ØA, et al. Utility of tear osmolarity measurement in diagnosis of dry eye disease[J]. Sci Rep, 2020, 10(1): 5542., articleTitle=null, refAbstract=null), Reference(id=1330225542361624818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A[J]. Proc Natl Acad Sci USA, 1992, 89(9): 3686-3690., articleTitle=null, refAbstract=null), Reference(id=1330225542424539379, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group[J]. Ophthalmology, 2000, 107(4): 631-639., articleTitle=null, refAbstract=null), Reference(id=1330225542500036852, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group[J]. Ophthalmology, 2000, 107(5): 967-974., articleTitle=null, refAbstract=null), Reference(id=1330225542596505845, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Stonecipher KG, Torkildsen GL, Ousler GW 3rd, et al. The impact study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye[J]. Clin Ophthalmol, 2016, 10: 887-895., articleTitle=null, refAbstract=null), Reference(id=1330225542663614710, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Hoy SM. Ciclosporin ophthalmic emulsion 0.1%: a review in severe dry eye disease[J]. Drugs, 2017, 77(17): 1909-1916., articleTitle=null, refAbstract=null), Reference(id=1330225542730723575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=De Paiva CS, Pflugfelder SC, Ng SM, et al. Topical cyclosporine a therapy for dry eye syndrome[J]. Cochrane Database Syst Rev, 2019, 9(9): CD010051., articleTitle=null, refAbstract=null), Reference(id=1330225542797832440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Goldberg DF, Malhotra RP, Schechter BA, et al. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease[J]. Ophthalmology, 2019, 126(9): 1230-1237., articleTitle=null, refAbstract=null), Reference(id=1330225542869135611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease[J]. Clin Ophthalmol, 2018, 12: 1921-1929., articleTitle=null, refAbstract=null), Reference(id=1330225542944633084, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease[J]. J Ocul Pharmacol Ther, 2011, 27(1): 23-27., articleTitle=null, refAbstract=null), Reference(id=1330225543053684989, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=Cutolo CA, Barabino S, Bonzano C, et al. The use of topical corticosteroids for treatment of dry eye syndrome[J]. Ocul Immunol Inflamm, 2019, 27(2): 266-275., articleTitle=null, refAbstract=null), Reference(id=1330225543124988158, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone[J]. Yonsei Med J, 2014, 55(1): 203-208., articleTitle=null, refAbstract=null), Reference(id=1330225543187902719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye[J]. Exp Eye Res, 2006, 83(3): 526-535., articleTitle=null, refAbstract=null), Reference(id=1330225543255011584, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study[J]. Am J Ophthalmol, 2003, 136(4): 593-602., articleTitle=null, refAbstract=null), Reference(id=1330225543313731841, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?[J]. Ophthalmol Ther, 2013, 2(2): 55-72., articleTitle=null, refAbstract=null), Reference(id=1330225543418589442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1)[J]. Cell, 1987, 51(5): 813-819., articleTitle=null, refAbstract=null), Reference(id=1330225543477309699, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=null, refType=null, unstructuredReference=Denucci CC, Mitchell JS, Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there[J]. Crit Rev Immunol, 2009, 29(2): 87-109., articleTitle=null, refAbstract=null), Reference(id=1330225543552807172, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[63], rfOrder=62, authorNames=null, journalName=null, refType=null, unstructuredReference=Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease[J]. Ocul Surf, 2016, 14(2): 207-215., articleTitle=null, refAbstract=null), Reference(id=1330225543619916037, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[64], rfOrder=63, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun Y, Zhang R, Gadek TR, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR1118)[J]. J Ocul Pharmacol Ther, 2013, 29(4): 395-402., articleTitle=null, refAbstract=null), Reference(id=1330225543687024902, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[65], rfOrder=64, authorNames=null, journalName=null, refType=null, unstructuredReference=Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)[J]. Ophthalmology, 2017, 124(1): 53-60., articleTitle=null, refAbstract=null), Reference(id=1330225543762522375, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[66], rfOrder=65, authorNames=null, journalName=null, refType=null, unstructuredReference=Donnenfeld ED, Perry HD, Nattis AS, et al. Lifitegrast for the treatment of dry eye disease in adults[J]. Expert Opin Pharmacother, 2017, 18(14): 1517-1524., articleTitle=null, refAbstract=null), Reference(id=1330225543829631242, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[67], rfOrder=66, authorNames=null, journalName=null, refType=null, unstructuredReference=Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study[J]. Ophthalmology, 2014, 121(2): 475-483., articleTitle=null, refAbstract=null), Reference(id=1330225543905128715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[68], rfOrder=67, authorNames=null, journalName=null, refType=null, unstructuredReference=Thulasi P, Djalilian AR. Update in current diagnostics and therapeutics of dry eye disease[J]. Ophthalmology, 2017, 124(11S): S27-S33., articleTitle=null, refAbstract=null), Reference(id=1330225543989014796, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[69], rfOrder=68, authorNames=null, journalName=null, refType=null, unstructuredReference=Higdon A, Diers AR, Oh JY, et al. Cell signalling by reactive lipid species: new concepts and molecular mechanisms[J]. Biochem J, 2012, 442(3): 453-464., articleTitle=null, refAbstract=null), Reference(id=1330225544085483789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[70], rfOrder=69, authorNames=null, journalName=null, refType=null, unstructuredReference=Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel rasp inhibitor, in dry eye disease[J]. J Ocul Pharmacol Ther, 2021, 37(4): 193-199., articleTitle=null, refAbstract=null), Reference(id=1330225544148398350, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[71], rfOrder=70, authorNames=null, journalName=null, refType=null, unstructuredReference=Clark D, Tauber J, Sheppard J, et al. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease[J]. Am J Ophthalmol, 2021, 226: 22-31., articleTitle=null, refAbstract=null), Reference(id=1330225544215507215, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[72], rfOrder=71, authorNames=null, journalName=null, refType=null, unstructuredReference=Sosne G, Siddiqi A, Kurpakus-Wheater M. Thymosin-beta4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro[J]. Invest Ophthalmol Vis Sci, 2004, 45(4): 1095-1100., articleTitle=null, refAbstract=null), Reference(id=1330225544286810384, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[73], rfOrder=72, authorNames=null, journalName=null, refType=null, unstructuredReference=Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair[J]. Nature, 2004, 432(7016): 466-472., articleTitle=null, refAbstract=null), Reference(id=1330225544366502161, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[74], rfOrder=73, authorNames=null, journalName=null, refType=null, unstructuredReference=Morris DC, Chopp M, Zhang L, et al. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke[J]. Neuroscience, 2010, 169(2): 674-682., articleTitle=null, refAbstract=null), Reference(id=1330225544441999634, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[75], rfOrder=74, authorNames=null, journalName=null, refType=null, unstructuredReference=Sosne G, Hafeez S, Greenberry AL 2nd, et al. Thymosin β4 promotes human conjunctival epithelial cell migration[J]. Curr Eye Res, 2002, 24(4): 268-273., articleTitle=null, refAbstract=null), Reference(id=1330225544500719891, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[76], rfOrder=75, authorNames=null, journalName=null, refType=null, unstructuredReference=Abelson R, Lane KJ, Rodriguez J, et al. A single-center study evaluating the effect of the controlled adverse environment (CAE(SM)) model on tear film stability[J]. Clin Ophthalmol, 2012, 6: 1865-1872., articleTitle=null, refAbstract=null), Reference(id=1330225544567828756, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[77], rfOrder=76, authorNames=null, journalName=null, refType=null, unstructuredReference=Kim CE, Kleinman HK, Sosne G, et al. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model[J]. Sci Rep, 2018, 8(1): 10500., articleTitle=null, refAbstract=null), Reference(id=1330225544639131925, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[78], rfOrder=77, authorNames=null, journalName=null, refType=null, unstructuredReference=魏传银, 王丽梅, 陈雪红, 等. 神经营养素受体p75NTR介导的信号转导[J]. 细胞与分子免疫学杂志, 2005, 21(2): 258-260., articleTitle=null, refAbstract=null), Reference(id=1330225544697852183, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[79], rfOrder=78, authorNames=null, journalName=null, refType=null, unstructuredReference=Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye[J]. Exp Eye Res, 2011, 93(4): 503-512., articleTitle=null, refAbstract=null), Reference(id=1330225546346213656, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[80], rfOrder=79, authorNames=null, journalName=null, refType=null, unstructuredReference=Esquenazi S, Bazan HE, Bui V, et al. Topical combination of NGF and DHA increases rabbit corneal nerve regeneration after photorefractive keratectomy[J]. Invest Ophthalmol Vis Sci, 2005, 46(9): 3121-3127., articleTitle=null, refAbstract=null), Reference(id=1330225548292370713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[81], rfOrder=80, authorNames=null, journalName=null, refType=null, unstructuredReference=Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical trial in patients with dry eye[J]. Clin Ophthalmol, 2013, 7: 1275-1285., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330225535726235835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, awardId=81872860, language=CN, fundingSource=国家自然科学基金项目(81872860), fundOrder=null, country=null), Fund(id=1330225537324265660, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, awardId=2019ZX09301104, language=CN, fundingSource=国家重大新药创制专项(2019ZX09301104), fundOrder=null, country=null), Fund(id=1330225537403957437, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, awardId=2017BT01Y093, language=CN, fundingSource=广东省“珠江人才计划”本土创新科研团队项目(2017BT01Y093), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330225534409224349, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=1., ext=[AuthorCompanyExt(id=1330225534417612958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China), AuthorCompanyExt(id=1330225534426001567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中山大学药学院,广东 广州 510275)]), AuthorCompany(id=1330225534480527520, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=2., ext=[AuthorCompanyExt(id=1330225534488916129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China), AuthorCompanyExt(id=1330225534501499042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.珠海联邦制药股份有限公司,广东 珠海 528467)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.05.022, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.05.022, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.05.022, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.05.022, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1652112000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
干眼症的用药研究进展
房淼 1, 2 , 王德刚 2 , 刘培庆 1, *
世界临床药物 | 综述评论 2022,43(5): 620-627
收起
收藏切换
世界临床药物 |综述评论 2022 , 43 (5) : 620 -627
干眼症的用药研究进展
全屏
[Author(id=1330225534576996516, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225534656688295, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534576996516, language=EN, stringName=Miao FANG, firstName=Miao, middleName=null, lastName=FANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China
2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225534736380072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534576996516, language=CN, stringName=房淼, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中山大学药学院,广东 广州 510275
2.珠海联邦制药股份有限公司,广东 珠海 528467, bio={"content":"

房淼,博士,研究方向:药理学。

"}, bioImg=null, bioContent=

房淼,博士,研究方向:药理学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225534409224349, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=1., ext=[AuthorCompanyExt(id=1330225534417612958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China), AuthorCompanyExt(id=1330225534426001567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中山大学药学院,广东 广州 510275)]), AuthorCompany(id=1330225534480527520, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=2., ext=[AuthorCompanyExt(id=1330225534488916129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China), AuthorCompanyExt(id=1330225534501499042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.珠海联邦制药股份有限公司,广东 珠海 528467)])]), Author(id=1330225534841237674, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225534933512364, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534841237674, language=EN, stringName=Degang WANG, firstName=Degang, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225534992232621, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225534841237674, language=CN, stringName=王德刚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.珠海联邦制药股份有限公司,广东 珠海 528467, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225534480527520, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=2., ext=[AuthorCompanyExt(id=1330225534488916129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China), AuthorCompanyExt(id=1330225534501499042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534480527520, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.珠海联邦制药股份有限公司,广东 珠海 528467)])]), Author(id=1330225535067730095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225535139033265, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225535067730095, language=EN, stringName=Peiqing LIU, firstName=Peiqing, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225535206142130, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, authorId=1330225535067730095, language=CN, stringName=刘培庆, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中山大学药学院,广东 广州 510275, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225534409224349, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, xref=1., ext=[AuthorCompanyExt(id=1330225534417612958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China), AuthorCompanyExt(id=1330225534426001567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225533830410392, companyId=1330225534409224349, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中山大学药学院,广东 广州 510275)])])]
房淼1, 2, 王德刚2, 刘培庆1, *
作者信息
  • 1.中山大学药学院,广东 广州 510275
  • 2.珠海联邦制药股份有限公司,广东 珠海 528467
通讯作者:
刘培庆,主任药师,教授,研究方向:心血管药理学。
作者简介:

房淼,博士,研究方向:药理学。

Advances in drug use for dry eye disease
Miao FANG1, 2, Degang WANG2, Peiqing LIU1, *
Affiliations
  • 1.School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510275, Guangdong Province, China
  • 2.Zhuhai United Laboratories Co., LTD., Zhuhai 528467, Guangdong Province, China
出版时间: 2022-05-10 doi: 10.13683/j.wph.2022.05.022
文章导航
收藏切换

干眼症(dry eye disease,DED)又称干燥性角膜结膜炎,是由于泪腺分泌不稳定导致泪液质或量异常及眼表损害,致使眼部出现如炎症、疼痛、发红及发痒等多种症状的一种疾病,环境及遗传等因素均可诱发DED。尽管目前已有多种针对DED的药物上市,但产品渗透率较低,因此临床仍有较大需求。该文就目前DED临床用药及全球DED在研药物的研究进展作一综述,以期为临床用药提供参考。

干眼症  /  眼表损害  /  临床用药

Dry eye disease (DED), also known as keratoconjunctivitis sicca (KCS), is a disease caused by unstable lacrimal gland secretion, which leads to abnormal tear quality or quantity and eye surface damage, resulting in a variety of ocular symptoms, such as inflammation, pain, redness and itching. DED can also induce by environmental and genetic factors. Although there are many kinds of drugs for DED on the market, the product penetration rate is low, so there is still a great demand in clinic. This paper reviewed the current clinical drug use of DED and the research progress of global drugs for DED in research, in order to provide reference for clinical drug use.

dry eye disease  /  ocular surface lesion  /  clinical medication
房淼, 王德刚, 刘培庆. 干眼症的用药研究进展. 世界临床药物, 2022 , 43 (5) : 620 -627 . DOI: 10.13683/j.wph.2022.05.022
Miao FANG, Degang WANG, Peiqing LIU. Advances in drug use for dry eye disease[J]. World Clinical Drug, 2022 , 43 (5) : 620 -627 . DOI: 10.13683/j.wph.2022.05.022
  • 国家自然科学基金项目(81872860)
  • 国家重大新药创制专项(2019ZX09301104)
  • 广东省“珠江人才计划”本土创新科研团队项目(2017BT01Y093)
参考文献 引证文献
排序方式:
[1]
中华医学会眼科学分会角膜病学组. 干眼临床诊疗专家共识(2013年)节选[J]. 中国社区医师, 2013, 29(21): 11-12.
[2]
杨建军. 巩膜扣带术和干眼的相关性的临床研究[D]. 广西: 广西中医药大学, 2019.
[3]
余穑婕, 陈子林. 干眼的定义与分类的研究现状[J]. 中国临床新医学, 2019, 12(7): 801-804.
[4]
McDonald M, Patel DA, Keith MS, et al. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review[J]. Ocul Surf, 2016, 14(2): 144-167.
[5]
Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index[J]. Arch Ophthalmol, 2000, 118(5): 615-621.
[6]
Grubbs JR Jr, Tolleson-Rinehart S, Huynh K, et al. A review of quality of life measures in dry eye questionnaires[J]. Cornea, 2014, 33(2): 215-218.
[7]
Anon. Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the international dry eye workshop (2007)[J]. Ocul Surf, 2007, 5(2): 108-152.
[8]
Bron AJ. Diagnosis of dry eye[J]. Surv Ophthalmol, 2001, 45(2): S221-S226.
[9]
张辉, 李艳芳, 管玉颜. 干眼症的临床诊断[J]. 中国实验诊断学, 2009, 13(7): 940-941.
[10]
Tomlinson A, Khanal S, Ramaesh K, et al. Tear film osmolarity: determination of a referent for dry eye diagnosis[J]. Invest Ophthalmol Vis Sci, 2006, 47(10): 4309-4315.
[11]
Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease[J]. Cornea, 2004, 23(8): 762-770.
[12]
Lemp MA. Management of dry eye disease[J]. Am J Manag Care, 2008, 14(3): S88-S101.
[13]
李谋, 史瑾, 杨小琳, 等. 人工泪液在干眼症中的应用进展[J]. 中国现代医生, 2018, 56(34): 162-164.
[14]
Choi HY, Lee YH, Lim CH, et al. Assessment of respiratory and systemic toxicity of benzalkonium chloride following a 14-day inhalation study in rats[J]. Part Fibre Toxicol, 2020, 17(1): 5.
[15]
Vitoux MA, Kessal K, Melik Parsadaniantz S, et al. Benzalkonium chloride-induced direct and indirect toxicity on corneal epithelial and trigeminal neuronal cells: proinflammatory and apoptotic responses in vitro[J]. Toxicol Lett, 2020, 319: 74-84.
[16]
Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells[J]. Adv Ther, 2011, 28(6): 501-510.
[17]
Kim YH, Jung JC, Jung SY, et al. Comparison of the efficacy of fluorometholone with and without benzalkonium chloride in ocular surface disease[J]. Cornea, 2016, 35(2): 234-242.
[18]
Epstein SP, Ahdoot M, Marcus E, et al. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells[J]. J Ocul Pharmacol Ther, 2009, 25(2): 113-119.
[19]
Ayaki M, Iwasawa A. Cell viability of four corneoconjunctival cell lines exposed to five preservatives and a surfactant used for infection control in eyedrops[J]. Biocontrol Sci, 2011, 16(3): 117-121.
[20]
Galletti JG, Gabelloni ML, Morande PE, et al. Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model[J]. Mucosal Immunol, 2013, 6(1): 24-34.
[21]
Lin Z, He H, Zhou T, et al. A mouse model of limbal stem cell deficiency induced by topical medication with the preservative benzalkonium chloride[J]. Invest Ophthalmol Vis Sci, 2013, 54(9): 6314-6325.
[22]
Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas[J]. Invest Ophthalmol Vis Sci, 1980, 19(3): 308-313.
[23]
Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye[J]. Cochrane Database Syst Rev, 2017, 2(2): CD009327.
[24]
Bradley JC, Bradley RH, McCartney DL, et al. Serum growth factor analysis in dry eye syndrome[J]. Clin Exp Ophthalmol, 2008, 36(8): 717-720.
[25]
Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease[J]. Br J Ophthalmol, 2004, 88(5): 647-652.
[26]
Moon J, Ko JH, Yoon CH, et al. Effects of 20% human serum on corneal epithelial toxicity induced by benzalkonium chloride: in vitro and clinical studies[J]. Cornea, 2018, 37(5): 617-623.
[27]
李海燕, 庞国祥. 眼表黏蛋白的研究进展[J]. 国际眼科纵览, 2004, 28(3): 150-154.
[28]
Stephens DN, McNamara NA. Altered mucin and glycoprotein expression in dry eye disease[J]. Optom Vis Sci, 2015, 92(9): 931-938.
[29]
Watanabe H. Medical treatment for dry eye in Japan[J]. Invest Ophthalmol Vis Sci, 2018, 59(14): DES116-DES120.
[30]
Kawashima M, Yamada M, Suwaki K, et al. A clinic-based survey of clinical characteristics and practice pattern of dry eye in Japan[J]. Adv Ther, 2017, 34(3): 732-743.
[31]
Cowlen MS, Zhang VZ, Warnock L, et al. Localization of ocular P2Y2 receptor gene expression by in situ hybridization[J]. Exp Eye Res, 2003, 77(1): 77-84.
[32]
Li Y, Kuang K, Yerxa B, et al. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl- and fluid secretion[J]. Am J Physiol Cell Physiol, 2001, 281(2): C595-C602.
[33]
Amano S, Inoue K. Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction[J]. Clin Ophthalmol, 2017, 11: 1677-1682.
[34]
Shigeyasu C, Hirano S, Akune Y, et al. Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects[J]. Curr Eye Res, 2015, 40(9): 878-883.
[35]
Hwang HS, Sung YM, Lee WS, et al. Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops[J]. Cornea, 2014, 33(9): 935-941.
[36]
Gong L, Sun X, Ma Z, et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore[J]. Br J Ophthalmol, 2015, 99(7): 903-908.
[37]
Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test[J]. Dig Dis Sci, 2009, 54(7): 1500-1507.
[38]
Kato K, Miyake K, Kondo N, et al. Conjunctival goblet cell density following cataract surgery with diclofenac versus diclofenac and rebamipide: a randomized trial[J]. Am J Ophthalmol, 2017, 181: 26-36.
[39]
Kashima T, Itakura H, Akiyama H, et al. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal[J]. Clin Ophthalmol, 2014, 8: 1003-1010.
[40]
Mantelli F, Argueso P. Functions of ocular surface mucins in health and disease[J]. Curr Opin Allergy Clin Immunol, 2008, 8(5): 477-483.
[41]
Arimoto A, Kitagawa K, Mita N, et al. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjogren syndrome patients with or without punctal occlusions[J]. Cornea, 2014, 33(8): 806-811.
[42]
Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients[J]. Cornea, 2009, 28(9): 1023-1027.
[43]
Baudouin C. A new approach for better comprehension of diseases of the ocular surface[J]. J Fr Ophtalmol, 2007, 30(3): 239-246.
[44]
Anon. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007)[J]. Ocul Surf, 2007, 5(2): 75-92.
[45]
Suzuki M, Massingale ML, Ye F, et al. Tear osmolarity as a biomarker for dry eye disease severity[J]. Invest Ophthalmol Vis Sci, 2010, 51(9): 4557-4561.
[46]
Tashbayev B, Utheim TP, Utheim ØA, et al. Utility of tear osmolarity measurement in diagnosis of dry eye disease[J]. Sci Rep, 2020, 10(1): 5542.
[47]
Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A[J]. Proc Natl Acad Sci USA, 1992, 89(9): 3686-3690.
[48]
Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group[J]. Ophthalmology, 2000, 107(4): 631-639.
[49]
Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group[J]. Ophthalmology, 2000, 107(5): 967-974.
[50]
Stonecipher KG, Torkildsen GL, Ousler GW 3rd, et al. The impact study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye[J]. Clin Ophthalmol, 2016, 10: 887-895.
[51]
Hoy SM. Ciclosporin ophthalmic emulsion 0.1%: a review in severe dry eye disease[J]. Drugs, 2017, 77(17): 1909-1916.
[52]
De Paiva CS, Pflugfelder SC, Ng SM, et al. Topical cyclosporine a therapy for dry eye syndrome[J]. Cochrane Database Syst Rev, 2019, 9(9): CD010051.
[53]
Goldberg DF, Malhotra RP, Schechter BA, et al. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease[J]. Ophthalmology, 2019, 126(9): 1230-1237.
[54]
Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease[J]. Clin Ophthalmol, 2018, 12: 1921-1929.
[55]
Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease[J]. J Ocul Pharmacol Ther, 2011, 27(1): 23-27.
[56]
Cutolo CA, Barabino S, Bonzano C, et al. The use of topical corticosteroids for treatment of dry eye syndrome[J]. Ocul Immunol Inflamm, 2019, 27(2): 266-275.
[57]
Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone[J]. Yonsei Med J, 2014, 55(1): 203-208.
[58]
De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye[J]. Exp Eye Res, 2006, 83(3): 526-535.
[59]
Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study[J]. Am J Ophthalmol, 2003, 136(4): 593-602.
[60]
Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?[J]. Ophthalmol Ther, 2013, 2(2): 55-72.
[61]
Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1)[J]. Cell, 1987, 51(5): 813-819.
[62]
Denucci CC, Mitchell JS, Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there[J]. Crit Rev Immunol, 2009, 29(2): 87-109.
[63]
Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease[J]. Ocul Surf, 2016, 14(2): 207-215.
[64]
Sun Y, Zhang R, Gadek TR, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR1118)[J]. J Ocul Pharmacol Ther, 2013, 29(4): 395-402.
[65]
Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)[J]. Ophthalmology, 2017, 124(1): 53-60.
[66]
Donnenfeld ED, Perry HD, Nattis AS, et al. Lifitegrast for the treatment of dry eye disease in adults[J]. Expert Opin Pharmacother, 2017, 18(14): 1517-1524.
[67]
Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study[J]. Ophthalmology, 2014, 121(2): 475-483.
[68]
Thulasi P, Djalilian AR. Update in current diagnostics and therapeutics of dry eye disease[J]. Ophthalmology, 2017, 124(11S): S27-S33.
[69]
Higdon A, Diers AR, Oh JY, et al. Cell signalling by reactive lipid species: new concepts and molecular mechanisms[J]. Biochem J, 2012, 442(3): 453-464.
[70]
Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel rasp inhibitor, in dry eye disease[J]. J Ocul Pharmacol Ther, 2021, 37(4): 193-199.
[71]
Clark D, Tauber J, Sheppard J, et al. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease[J]. Am J Ophthalmol, 2021, 226: 22-31.
[72]
Sosne G, Siddiqi A, Kurpakus-Wheater M. Thymosin-beta4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro[J]. Invest Ophthalmol Vis Sci, 2004, 45(4): 1095-1100.
[73]
Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair[J]. Nature, 2004, 432(7016): 466-472.
[74]
Morris DC, Chopp M, Zhang L, et al. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke[J]. Neuroscience, 2010, 169(2): 674-682.
[75]
Sosne G, Hafeez S, Greenberry AL 2nd, et al. Thymosin β4 promotes human conjunctival epithelial cell migration[J]. Curr Eye Res, 2002, 24(4): 268-273.
[76]
Abelson R, Lane KJ, Rodriguez J, et al. A single-center study evaluating the effect of the controlled adverse environment (CAE(SM)) model on tear film stability[J]. Clin Ophthalmol, 2012, 6: 1865-1872.
[77]
Kim CE, Kleinman HK, Sosne G, et al. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model[J]. Sci Rep, 2018, 8(1): 10500.
[78]
魏传银, 王丽梅, 陈雪红, 等. 神经营养素受体p75NTR介导的信号转导[J]. 细胞与分子免疫学杂志, 2005, 21(2): 258-260.
[79]
Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye[J]. Exp Eye Res, 2011, 93(4): 503-512.
[80]
Esquenazi S, Bazan HE, Bui V, et al. Topical combination of NGF and DHA increases rabbit corneal nerve regeneration after photorefractive keratectomy[J]. Invest Ophthalmol Vis Sci, 2005, 46(9): 3121-3127.
[81]
Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical trial in patients with dry eye[J]. Clin Ophthalmol, 2013, 7: 1275-1285.
2022年第43卷第5期
9
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.05.022
  • 接收时间:2021-07-17
  • 首发时间:2026-11-19
  • 出版时间:2022-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-07-17
基金
国家自然科学基金项目(81872860)
国家重大新药创制专项(2019ZX09301104)
广东省“珠江人才计划”本土创新科研团队项目(2017BT01Y093)
作者信息
    1.中山大学药学院,广东 广州 510275
    2.珠海联邦制药股份有限公司,广东 珠海 528467

通讯作者:

刘培庆,主任药师,教授,研究方向:心血管药理学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.05.022
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏